Jones Trading analyst Catherine Novack downgraded Capricor Therapeutics (NASDAQ: CAPR) from Buy to Hold.The analyst comments "What's New: An FDA ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE